“They’ve now announced that people who received both therapies were 49% less likely to experience recurrence or death a median of three years after treatment compared to people in the Keytruda-only group.”
Moderna and Merck personalize mRNA-4157 for each patient, coding up to 34 neoantigens from that person’s own melanoma. The 2022 result was 44%, and three years later it held at 49%. The trial had 157 participants, so the phase 3 with more than 1,000 people is the real test. Moderna’s CEO is already talking about accelerated approval by 2025.